Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA

Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,333,340 shares of the company’s stock, valued at approximately $25,640,000. Oruka Therapeutics accounts for about 0.3% of Avoro Capital Advisors LLC’s portfolio, making the stock its 24th largest position. Avoro Capital Advisors LLC owned about 3.21% of Oruka Therapeutics as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new stake in shares of Oruka Therapeutics in the 1st quarter valued at $2,505,000. Geode Capital Management LLC increased its stake in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after purchasing an additional 354,821 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Oruka Therapeutics during the second quarter worth about $68,000. Intech Investment Management LLC acquired a new stake in shares of Oruka Therapeutics during the second quarter worth about $168,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares during the period. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. This trade represents a 17.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 21,000 shares of company stock valued at $663,530. 24.69% of the stock is currently owned by company insiders.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday. BTIG Research reissued a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a research report on Friday. Barclays upped their price objective on Oruka Therapeutics from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday. UBS Group started coverage on Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.67.

Oruka Therapeutics Trading Up 25.0%

Shares of ORKA stock opened at $40.00 on Friday. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $41.19. The business’s 50 day moving average is $32.92 and its two-hundred day moving average is $27.50. The company has a market capitalization of $1.94 billion, a P/E ratio of -21.51 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. As a group, equities analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.